Short-term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia

American Journal of Medicine

Volumn 124, Issue 10, 2011, Pages

  Jaber, Bertrand L ^a,b   Almarzouqi, Leena ^a,b   Borgi, Lea ^a,b   Seabra, Victor F ^a,b   Balk, Ethan M ^b,c   Madias, Nicolaos E ^a,b  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

Conivaptan; Hyponatremia; Lixivaptan; Satavaptan; Tolvaptan

Indexed keywords

CONIVAPTAN; LIXIVAPTAN; SATAVAPTAN; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST;

ARTICLE; COMPARATIVE STUDY; DEATH; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EFFECTIVE WATER CLEARANCE; EUVOLEMIC HYPONATREMIA; HEADACHE; HUMAN; HYPERNATREMIA; HYPERVOLEMIC HYPONATREMIA; HYPONATREMIA; HYPOTENSION; INFUSION SITE PHLEBITIS; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; MEDLINE; META ANALYSIS; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SODIUM BLOOD LEVEL; THIRST; TREATMENT DURATION; WATER METABOLISM;

HUMANS; HYPONATREMIA; ODDS RATIO; RECEPTORS, VASOPRESSIN; SODIUM;

EID: 80053391504     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.04.028     Document Type: Article

References (40)

1. H.J. Adrogue, and N.E. Madias Hyponatremia N Engl J Med 342 21 2000 1581 1589 (Pubitemid 30340505)
2. A. Upadhyay, B.L. Jaber, and N.E. Madias Incidence and prevalence of hyponatremia Am J Med 119 7 Suppl 1 2006 S30 S35
3. A. Upadhyay, B.L. Jaber, and N.E. Madias Epidemiology of hyponatremia Semin Nephrol 29 3 2009 227 238
4. S.S. Waikar, D.B. Mount, and G.C. Curhan Mortality after hospitalization with mild, moderate, and severe hyponatremia Am J Med 122 9 2009 857 865
5. R. Wald, B.L. Jaber, L.L. Price, A. Upadhyay, and N.E. Madias Impact of hospital-associated hyponatremia on selected outcomes Arch Intern Med 170 3 2010 294 302
6. A. Greenberg, and J.G. Verbalis Vasopressin receptor antagonists Kidney Int 69 12 2006 2124 2130 (Pubitemid 43882098)
7. J.G. Verbalis, S.R. Goldsmith, A. Greenberg, R.W. Schrier, and R.H. Sterns Hyponatremia treatment guidelines 2007: expert panel recommendations Am J Med 120 11 Suppl 1 2007 S1 S21
8. M.K. Nguyen, and I. Kurtz Derivation of a new formula for calculating urinary electrolyte-free water clearance based on the Edelman equation Am J Physiol Renal Physiol 288 1 2005 F1 F7
9. A.R. Jadad, R.A. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1 1996 1 12 (Pubitemid 26120810)
10. V.F. Seabra, S. Alobaidi, E.M. Balk, A.H. Poon, and B.L. Jaber Off-pump coronary artery bypass surgery and acute kidney injury: a meta-analysis of randomized controlled trials Clin J Am Soc Nephrol 5 10 2010 1734 1744
11. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 3 1986 177 188 (Pubitemid 17189972)
12. G. Rucker, G. Schwarzer, J. Carpenter, and I. Olkin Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells Stat Med 28 5 2009 721 738
13. T. Huedo-Medina, J. Sanchez-Meca, F. Marin-Martinez, and J. Botella Assessing heterogeneity in meta-analysis: Q statistic or I2 index? CHIP Documents 2006 Paper 19 http://digitalcommons.uconn.edu/chip-docs/19 Accessed July 13, 2011
14. B.C. Wallace, C.H. Schmid, J. Lau, and T.A. Trikalinos Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data BMC Med Res Methodol 9 2009 80
15. R.J. Harris, M.J. Bradburn, J.J. Deeks, R.M. Harbord, D.G. Altman, and J.A.C. Sterne Metan: fixed- and random-effects meta-analysis Stata J 8 2008 28
16. F. Wong, A.T. Blei, L.M. Blendis, and P.J. Thuluvath A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial Hepatology 37 1 2003 182 191 (Pubitemid 36042159)
17. J.K. Ghali, M.J. Koren, and J.R. Taylor Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia J Clin Endocrinol Metab 91 6 2006 2145 2152 (Pubitemid 43854997)
18. R.W. Schrier, P. Gross, and M. Gheorghiade Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia N Engl J Med 355 20 2006 2099 2112 (Pubitemid 44749318)
19. A. Soupart, P. Gross, and J.J. Legros Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist Clin J Am Soc Nephrol 1 6 2006 1154 1160
20. G. Decaux, A. Soupart, A. Finta, and S. Alfoldi Randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of satavaptan (SR121463B) in patients with SIADH [abstract] J Am Soc Nephrol 19 2006 588A
21. M. Gheorghiade, S.S. Gottlieb, and J.E. Udelson Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia Am J Cardiol 97 7 2006 1064 1067
22. D. Zeltser, S. Rosansky, H. van Rensburg, J.G. Verbalis, N. Smith Conivaptan Study Group Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia Am J Nephrol 27 5 2007 447 457 (Pubitemid 47482001)
23. D. Aronson, J. Verbalis, M. Mueller, H. Krum DILIPO investigators Satavaptan, a vasopressin V2 receptor antagonist, for the treatment of dilutional hyponatremia (abstract) J Am Soc Nephrol 18 2007 790A
24. P. Gines, F. Wong, and H. Watson Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial Hepatology 48 1 2008 204 213 (Pubitemid 351975545)
25. D. Annane, G. Decaux, N. Smith Conivaptan Study Group Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia Am J Med Sci 337 1 2009 28 36
26. J.G. Verbalis, D. Zeltser, N. Smith, A. Barve, and M. Andoh Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study Clin Endocrinol (Oxf) 69 1 2008 159 168 (Pubitemid 351847263)
27. N.E. Madias Effects of tolvaptan, an oral vasopressin V2 receptor antagonist, in hyponatremia Am J Kidney Dis 50 2 2007 184 187 (Pubitemid 47095092)
28. T. Berl, F. Quittnat-Pelletier, and J.G. Verbalis Oral tolvaptan is safe and effective in chronic hyponatremia J Am Soc Nephrol 21 4 2010 705 712
29. G. Decaux V2-antagonists for the treatment of hyponatraemia Nephrol Dial Transplant 22 7 2007 1853 1855 (Pubitemid 47244752)
30. B.J. Feldman, S.M. Rosenthal, and G.A. Vargas Nephrogenic syndrome of inappropriate antidiuresis N Engl J Med 352 18 2005 1884 1890 (Pubitemid 40627814)
31. G. Decaux, F. Vandergheynst, Y. Bouko, J. Parma, G. Vassart, and C. Vilain Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree J Am Soc Nephrol 18 2 2007 606 612 (Pubitemid 46193326)
32. B. Rozen-Zvi, D. Yahav, M. Gheorghiade, A. Korzets, L. Leibovici, and U. Gafter Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis Am J Kidney Dis 56 2 2010 325 337
33. M.A. Konstam, M. Gheorghiade, and J.C. Burnett Jr Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial JAMA 297 12 2007 1319 1331 (Pubitemid 46513233)
34. M. Gheorghiade, M.A. Konstam, and J.C. Burnett Jr Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials JAMA 297 12 2007 1332 1343 (Pubitemid 46513234)
35. G. Decaux, A. Soupart, and G. Vassart Non-peptide arginine-vasopressin antagonists: the vaptans Lancet 371 9624 2008 1624 1632 (Pubitemid 351626846)
36. M. Gheorghiade, W.A. Gattis, and C.M. O'Connor Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial JAMA 291 16 2004 1963 1971 (Pubitemid 38544277)
37. G. Decaux Is asymptomatic hyponatremia really asymptomatic? Am J Med 119 7 Suppl 1 2006 S79 S82
38. B. Renneboog, W. Musch, X. Vandemergel, M.U. Manto, and G. Decaux Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits Am J Med 119 1 2006 71.e1 71.e8
39. J.G. Verbalis, J. Barsony, and Y. Sugimura Hyponatremia-induced osteoporosis J Bone Miner Res 25 3 2010 554 563
40. J. Barsony, Y. Sugimura, and J.G. Verbalis Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss J Biol Chem 286 12 2011 10864 10875